vs
Side-by-side financial comparison of Spero Therapeutics, Inc. (SPRO) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $11.5M, roughly 1.1× TRANSACT TECHNOLOGIES INC). On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 11.9%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 3.5%).
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
SPRO vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.6M | $11.5M |
| Net Profit | $31.5M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | — | -10.1% |
| Net Margin | 250.7% | — |
| Revenue YoY | 24080.8% | 11.9% |
| Net Profit YoY | 250.9% | — |
| EPS (diluted) | $0.56 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.6M | $11.5M | ||
| Q3 25 | $0 | $13.2M | ||
| Q2 25 | $0 | $13.8M | ||
| Q1 25 | $12.0K | $13.1M | ||
| Q4 24 | $52.0K | $10.2M | ||
| Q3 24 | $65.0K | $10.9M | ||
| Q2 24 | $114.0K | $11.6M | ||
| Q1 24 | $140.0K | $10.7M |
| Q4 25 | $31.5M | — | ||
| Q3 25 | $-7.4M | $15.0K | ||
| Q2 25 | $-1.7M | $-143.0K | ||
| Q1 25 | $-13.9M | $19.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-17.1M | $-551.0K | ||
| Q2 24 | $-17.9M | $-319.0K | ||
| Q1 24 | $-12.7M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | — | -10.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | -1.9% | ||
| Q1 25 | -122758.3% | -0.1% | ||
| Q4 24 | — | -10.3% | ||
| Q3 24 | -28604.6% | -7.7% | ||
| Q2 24 | -16720.2% | -3.8% | ||
| Q1 24 | -9987.1% | -12.2% |
| Q4 25 | 250.7% | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | -1.0% | ||
| Q1 25 | -115550.0% | 0.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -26380.0% | -5.1% | ||
| Q2 24 | -15668.4% | -2.8% | ||
| Q1 24 | -9049.3% | -9.7% |
| Q4 25 | $0.56 | $-0.11 | ||
| Q3 25 | $-0.13 | $0.00 | ||
| Q2 25 | $-0.03 | $-0.01 | ||
| Q1 25 | $-0.25 | $0.00 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | $-0.32 | $-0.06 | ||
| Q2 24 | $-0.33 | $-0.03 | ||
| Q1 24 | $-0.24 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.3M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $59.0M | $31.1M |
| Total Assets | $68.9M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.3M | $20.4M | ||
| Q3 25 | $48.6M | $20.0M | ||
| Q2 25 | $31.2M | $17.7M | ||
| Q1 25 | $48.9M | $14.2M | ||
| Q4 24 | $52.9M | $14.4M | ||
| Q3 24 | $76.3M | $11.3M | ||
| Q2 24 | $63.5M | $11.1M | ||
| Q1 24 | $82.3M | $10.6M |
| Q4 25 | $59.0M | $31.1M | ||
| Q3 25 | $26.5M | $31.8M | ||
| Q2 25 | $32.8M | $31.3M | ||
| Q1 25 | $33.8M | $30.9M | ||
| Q4 24 | $46.1M | $30.6M | ||
| Q3 24 | $65.5M | $38.4M | ||
| Q2 24 | $80.5M | $38.5M | ||
| Q1 24 | $96.2M | $38.6M |
| Q4 25 | $68.9M | $44.8M | ||
| Q3 25 | $54.2M | $45.0M | ||
| Q2 25 | $62.1M | $44.5M | ||
| Q1 25 | $77.7M | $44.2M | ||
| Q4 24 | $110.5M | $44.0M | ||
| Q3 24 | $135.2M | $50.5M | ||
| Q2 24 | $149.9M | $50.4M | ||
| Q1 24 | $167.7M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.4M | $609.0K |
| Free Cash FlowOCF − Capex | — | $589.0K |
| FCF MarginFCF / Revenue | — | 5.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | -0.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.4M | $609.0K | ||
| Q3 25 | $17.4M | $3.6M | ||
| Q2 25 | $-17.7M | $3.6M | ||
| Q1 25 | $-4.0M | $-161.0K | ||
| Q4 24 | $-23.4M | $2.4M | ||
| Q3 24 | $12.8M | $327.0K | ||
| Q2 24 | $-18.7M | $636.0K | ||
| Q1 24 | $5.9M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | -0.26× | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
